BOSTON, Aug. 11, 2016 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Nymox Pharmaceutical Corporation ("Nymox" or the "Company") (NASDAQ: NYMX) and certain of its officers and directors violated federal securities laws.
Nymox shares plummeted nearly 41% on August 10, 2016, after an article titled "Nymox: This Offshore 'Biotech' Promotion Will Go To Zero (Yes, Zero)" was published on the investment research site Seeking Alpha, reporting that Nymox has and continues to mislead shareholders about the Company's prospects, while "dumping millions in stock without making timely SEC disclosures." The revelation of Nymox's fraudulent conduct has caused tens of millions in losses to Nymox investors.
If you purchased or otherwise acquired Nymox securities prior to August 10, 2016 and have questions about your legal rights or possess information relevant to this investigation, please contact attorneys Steven Harte or Bradley Vettraino at (617) 398-5600, by email at email@example.com or firstname.lastname@example.org, or visit www.blockesq.com/nymox.
Confidentiality to whistleblowers or others with information relevant to the lawsuit is assured.
Block & Leviton LLP is a Boston-based law firm representing investors nationwide. The firm's lawyers have collectively been prosecuting securities cases on behalf of individual and institutional investors for over 100 years, and have recovered billions of dollars on their behalf. Block & Leviton's investigations into corporate wrongdoing were recently covered by the New York Times.
This notice may constitute attorney advertising.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nymox-pharmaceutical-corporation-investigated-for-securities-fraud-by-block--leviton-after-report-reveals-pervasive-misconduct-by-the-company-300312125.html
SOURCE Block & Leviton LLP